Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding EMPAVELI and SYFOVRE to strengthen its immunology and rare disease portfolio.
Written By: Sana Khan BPharm and
Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Biogen has agreed to acquire Apellis Pharmaceuticals in a $5.6 billion deal, adding two marketed complement-targeting therapies and a specialized commercial infrastructure to accelerate its push into immunology, nephrology, and rare diseases. The transaction includes a cash payment of $41 per share along with contingent value rights (CVRs) tied to future sales of SYFOVRE, and is expected to close in the second quarter of 2026, subject to regulatory approvals.
Two Marketed Drugs Add Immediate Revenue Visibility
At the core of the acquisition are two approved therapies EMPAVELI and SYFOVRE which together generated $689 million in 2025 and are expected to grow at 15–19% annually through 2028
EMPAVELI is approved across multiple rare indications, including C3 glomerulopathy, primary immune-complex membranoproliferative glomerulonephritis, and paroxysmal nocturnal hemoglobinuria, positioning it as a foundational asset in complement-driven kidney and hematologic diseases. SYFOVRE, meanwhile, is the first approved therapy for geographic atrophy, addressing a major unmet need in retinal disease.
Clinical Strength Rooted in Complement Biology
Both assets target complement component C3, a central driver of immune-mediated disease. In the Phase 3 VALIANT study, EMPAVELI demonstrated a 68% reduction in proteinuria along with stabilization of kidney function and clearance of C3 deposits.
SYFOVRE, supported by Phase 3 OAKS and DERBY studies, reduced lesion growth in geographic atrophy, with increasing benefit over time and long-term data suggesting a delay in disease progression by approximately 1.5 years in certain patients.
Strategic Expansion into Nephrology and Immunology
Beyond the marketed assets, Apellis brings an established U.S. commercial infrastructure, particularly in nephrology, which Biogen plans to leverage to support its late-stage pipeline. This includes felzartamab, currently in Phase 3 development across multiple kidney diseases, with initial readouts expected in 2027. The integration is expected to strengthen Biogen’s positioning in immune-mediated renal diseases while expanding its broader immunology franchise.
Biogen will also continue to collaborate with Sobi, which retains ex-U.S. commercial rights to EMPAVELI, ensuring continuity in global commercialization.
Deal Structure and Financial Upside
The deal includes additional payments to shareholders if SYFOVRE achieves key sales milestones, including thresholds of $1.5 billion and $2 billion in annual global net sales between 2027 and 2030, or a later payout if milestones are met in 2031. Biogen expects the deal to start adding to its adjusted profit per share from 2027, support steady long-term earnings growth, and deleverage by the end of 2027.
Christopher A. Viehbacher, Biogen’s President and Chief Executive Officer said the acquisition aligns with Biogen’s transformation strategy, strengthening its immunology and rare disease portfolio while advancing its nephrology ambitions and long-term growth profile.
Cedric Francois, M.D., Ph.D., co-founder and Chief Executive Officer of Apellis described the deal as a validation of Apellis’ complement science and execution, noting that Biogen’s scale and expertise will help expand the reach and impact of its therapies.
With this acquisition, Biogen secures immediate revenue-generating assets, deepens its presence in complement biology, and builds a stronger foundation in nephrology and retinal disease. The addition of Apellis positions the company to deliver both near-term commercial growth and longer-term pipeline expansion, marking a key step in its ongoing strategic transformation.
References
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology, March31,2026. https://investors.biogen.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology, March 31, 2026 https://investors.apellis.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio
About the Writer
Sana Jamil Khan is a B.Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.
About the Writer
Chikkula Pavan Kumar, Pharm.D is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.